ESR1 and breast cancer: This result was somewhat surprising, given previous reports suggesting that CCND1 amplification is one of the cardinal features of aggressive ER+ breast cancers, that the expression of the CCND1 gene is induced by estrogens, and that its amplification affects clinical response to tamoxifen.